Noninvasive prediction of the clinical benefit of immunotherapy in hepatocellular carcinoma
- PMID: 40447887
- DOI: 10.1007/s00535-025-02251-x
Noninvasive prediction of the clinical benefit of immunotherapy in hepatocellular carcinoma
Abstract
Long-term survival following a diagnosis of hepatocellular carcinoma (HCC) is greatly diminished when transplantation and surgical resection are ruled out. Fortunately, the advent of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of advanced unresectable HCC (uHCC), prolonging median survival by over a year. T lymphocytes normally eliminate neoplastic cells, but some tumors suppress this response by binding to immune checkpoint receptors. Blocking this interaction via ICIs restores immune-mediated targeting of cancer cells. While ICI-based combination immunotherapy is currently recommended as the first-line systemic therapy for uHCC, the objective radiological response rate remains limited to 20-30%, as not all tumors exploit this mechanism. Consequently, strategies are being explored to modulate the immune microenvironment into a "hot" environment more responsive to ICIs by combining local therapies such as transarterial chemoembolization, ablation, and radiation therapy. Therapeutic options have also expanded beyond ICIs, emphasizing the importance of selecting the most appropriate treatment. Therefore, the development of biomarkers capable of predicting the efficacy of immunotherapy is a priority. Direct evaluation of immune cell infiltration through biopsy is currently the most effective method but involves issues such as invasiveness and susceptibility to sampling bias. In this review, we aim to highlight promising non-invasive biomarkers and scoring systems that have the potential to improve treatment outcomes, including blood-based biomarkers such as lymphocyte ratios, cytokines, C-reactive protein, and alpha-fetoprotein; imaging biomarkers such as MRI, ultrasound, and contrast-enhanced CT; and other clinical indicators such as sarcopenia, grip strength, and diversity of the gut microbiome.
Keywords: Biomarker; Hepatocellular carcinoma; Immune checkpoint inhibitor; Immune microenvironment; Prediction.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflict of interest: Conflict of Interest Statement; TK received lecture fees from AstraZeneca K.K., Eisai Co., Ltd. and Chugai Pharmaceutical CO., Ltd.
Similar articles
-
Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.Front Immunol. 2021 Nov 26;12:783236. doi: 10.3389/fimmu.2021.783236. eCollection 2021. Front Immunol. 2021. PMID: 34899747 Free PMC article. Review.
-
Transarterial chemoembolization combined with molecular targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma beyond the up-to-seven criteria: a propensity score-matching analysis.Ann Med. 2024 Dec;56(1):2419993. doi: 10.1080/07853890.2024.2419993. Epub 2024 Nov 1. Ann Med. 2024. PMID: 39484705 Free PMC article.
-
Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.BMC Cancer. 2023 Jun 15;23(1):547. doi: 10.1186/s12885-023-11003-0. BMC Cancer. 2023. PMID: 37322411 Free PMC article.
-
The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.Front Immunol. 2022 May 23;13:913464. doi: 10.3389/fimmu.2022.913464. eCollection 2022. Front Immunol. 2022. PMID: 35677059 Free PMC article.
-
Radiation therapy in the era of immune treatment for hepatocellular carcinoma.Front Immunol. 2023 Jan 20;14:1100079. doi: 10.3389/fimmu.2023.1100079. eCollection 2023. Front Immunol. 2023. PMID: 36742293 Free PMC article. Review.
Cited by
-
Mendelian randomization analysis of inflammatory biomarkers and hepatocellular carcinoma risk: genetic causality and single-cell transcriptomics.Discov Oncol. 2025 Aug 7;16(1):1500. doi: 10.1007/s12672-025-03357-7. Discov Oncol. 2025. PMID: 40775116 Free PMC article.
References
-
- Vogel A, Chan SL, Dawson LA, et al. Hepatocellular carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025. https://doi.org/10.1016/j.annonc.2025.02.006 . - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials